Related Experiment Video

Updated: Jan 12, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

12.5K

Overdue: Delayed Revision of Institutional Review Board Policies Characterizing Pregnant Women After the Revised

Caleigh Propes1, Stephanie R Morain1

  • 1Johns Hopkins Berman Institute of Bioethics, and Department of Health Policy & Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (C.P., S.R.M.).

Annals of Internal Medicine
|November 3, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

10.3K
Author Spotlight: Inducing Pseudopregnancy in Female Mice Without the Need for Vasectomized Males Prior to Non-Surgical Embryo Transfer or Artificial Insemination
05:36

Author Spotlight: Inducing Pseudopregnancy in Female Mice Without the Need for Vasectomized Males Prior to Non-Surgical Embryo Transfer or Artificial Insemination

Published on: July 7, 2023

9.7K

Related Experiment Videos

Last Updated: Jan 12, 2026

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting
14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

12.5K
Working with Human Tissues for Translational Cancer Research
07:48

Working with Human Tissues for Translational Cancer Research

Published on: November 26, 2015

10.3K
Author Spotlight: Inducing Pseudopregnancy in Female Mice Without the Need for Vasectomized Males Prior to Non-Surgical Embryo Transfer or Artificial Insemination
05:36

Author Spotlight: Inducing Pseudopregnancy in Female Mice Without the Need for Vasectomized Males Prior to Non-Surgical Embryo Transfer or Artificial Insemination

Published on: July 7, 2023

9.7K

Related Concept Videos

Teratogenicity01:07

Teratogenicity

3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K

Articles linked to this work by shared authors, journal, and citation graph.

IRB Policies on the Inclusion of Pregnant Women in Research.

Ethics & human research·2026

A paradoxical plus for Parkinson's in UK's new 'generational smoking ban'.

Journal of Parkinson's disease·2026

A Framework of Institutional Obligations for Pragmatic Clinical Trials.

The American journal of bioethics : AJOB·2026

Systematic review of approaches to informed consent in recent high-impact clinical trials.

Journal of clinical and translational science·2026

Designing Consent Processes for Research With Older Adults Who May Lack Decisional Capacity: A Guide for Investigators.

Journal of the American Geriatrics Society·2026

Empirical research related to the ethics of pragmatic clinical trials: A scoping review.

Learning health systems·2026

Interventions to Improve Outpatient Follow-up for Hospitalized Patients With Alcohol Use Disorder : A Systematic Review.

Annals of internal medicine·2026

Association Between Blood Hemoglobin Concentration and Mortality by Age and Sex : A Prospective Cohort Study.

Annals of internal medicine·2026

Tuberculosis.

Annals of internal medicine·2026

Periconception Parental Red Blood Cell Folate, Vitamin B12, and Birth Defects in Offspring : A Prospective Cohort Study.

Annals of internal medicine·2026

In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y.

Annals of internal medicine·2026

In HFmrEF or HFrEF, digitalis glycosides reduce a composite of CV death or worsening HF event vs. placebo at a median 36 to 37 mo.

Annals of internal medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us